|
Stakeholders Push for Same Name for Biosimilars in Letter to Hamburg
Proponents of biosimilars carrying the same name as their reference biologic got a boost from a coalition of consumer advocates who penned a letter to FDA Commissioner Margaret Hamburg urging same-name use.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives